Related references
Note: Only part of the references are listed.Post-renal transplant surgical complications with newer immunosuppressive drugs: mycophenolate mofetil vs. m-TOR inhibitors
Aneesh Srivastava et al.
INTERNATIONAL UROLOGY AND NEPHROLOGY (2010)
Opposing roles for calcineurin and ATF3 in squamous skin cancer
Xunwei Wu et al.
NATURE (2010)
Incidence of Delayed Graft Function and Wound Healing Complications After Deceased-Donor Kidney Transplantation Is not Affected by De Novo Everolimus
Laetitia Albano et al.
TRANSPLANTATION (2009)
Multidisciplinary insights on clinical guidance for the use of proliferation signal inhibitors in heart transplantation
Andreas Zuckermann et al.
JOURNAL OF HEART AND LUNG TRANSPLANTATION (2008)
Adverse Effects of Mammalian Target of Rapamycin Inhibitors During the Postoperative Period After Cardiac Transplantation
A. Bouzas-Mosquera et al.
TRANSPLANTATION PROCEEDINGS (2008)
Use of Everolimus in De Novo Renal Recipients: Initial Experience in the Greek Population
V. Papanikolaou et al.
TRANSPLANTATION PROCEEDINGS (2008)
Tacrolimus with mycophenolate mofetil (MMF) or sirolimus vs. Cyclosporine with MMF in cardiac transplant patients: 1-year report
JA Kobashigawa et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2006)
Wound healing complications with de novo sirolimus versus mycophenolate mofetil-based regimen in cardiac transplant recipients
S Kuppahally et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2006)
Two-year incidence of malignancy in sirolimus-treated renal transplant recipients: results from five multicenter studies
T Mathew et al.
CLINICAL TRANSPLANTATION (2004)
Sirolimus in de novo heart transplant recipients reduces acute rejection and prevents coronary artery disease at 2 years - A randomized clinical trial
A Keogh et al.
CIRCULATION (2004)
Wound-healing complications after kidney transplantation: A prospective, randomized comparison of sirolimus and tacrolimus
PG Dean et al.
TRANSPLANTATION (2004)
Medical progress - Skin cancers after organ transplantation
S Euvrard et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor
M Guba et al.
NATURE MEDICINE (2002)
Share Paper
